Spots Global Cancer Trial Database for advanced ovarian cancer
Every month we try and update this database with for advanced ovarian cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer | NCT05794659 | Advanced Ovaria... | AST-201 Paclitaxel Carboplatin Placebo rhuGM-CSF(Granu... | 18 Years - | Aston Sci. Inc. | |
| Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer | NCT03693248 | Ovarian Cancer ... Ovarian Cancer ... Fallopian Tube ... Peritoneal Canc... | Two cycles of n... | 20 Years - 80 Years | Seoul National University Hospital | |
| A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer | NCT03292172 | Advanced Ovaria... Triple Negative... | Atezolizumab RO6870810 | 18 Years - | Hoffmann-La Roche | |
| Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer | NCT01462149 | Advanced Ovaria... | Neoadjuvant che... Carboplatin | 20 Years - 80 Years | Asan Medical Center | |
| Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients | NCT03737643 | Advanced Ovaria... | Bevacizumab Durvalumab Olaparib Placebo olapari... Durvalumab plac... Carboplatin+Pac... | 18 Years - 130 Years | AstraZeneca | |
| Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer | NCT00477282 | Ovarian Cancer | Karenitecin Topotecan | 18 Years - | BioNumerik Pharmaceuticals, Inc. | |
| A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer | NCT03292172 | Advanced Ovaria... Triple Negative... | Atezolizumab RO6870810 | 18 Years - | Hoffmann-La Roche | |
| Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. | NCT01844986 | Newly Diagnosed Advanced Ovaria... FIGO Stage III-... BRCA Mutation Complete Respon... Partial Respons... First Line Plat... | Olaparib 300mg ... | 18 Years - 130 Years | AstraZeneca | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer | NCT00831636 | Ovarian Cancer | CP-4055 CP-4055 | 18 Years - | Clavis Pharma | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| Primary Debulking Surgery Including Bowel Resection in Advanced Stage Ovarian Cancer Using Caiman® Technology | NCT03219242 | Ovarian Cancer | Caiman® device | 18 Years - 75 Years | Catholic University of the Sacred Heart | |
| Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer | NCT04360629 | Advanced Ovaria... | Tranexamic Acid normal saline | 20 Years - 70 Years | Fudan University | |
| To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers | NCT02179970 | Pancreatic Aden... Ovarian Serous ... Colorectal Canc... | Plerixafor | 16 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors | NCT01290471 | Advanced Solid ... Advanced Ovaria... | U3-1565 | 18 Years - | Daiichi Sankyo | |
| Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP® | NCT03878849 | Advanced Ovaria... | 2X-121 2X-121 DRP® | 18 Years - | Allarity Therapeutics | |
| To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers | NCT02179970 | Pancreatic Aden... Ovarian Serous ... Colorectal Canc... | Plerixafor | 16 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| Plasmodium Immunotherapy for Advanced Ovarian Cancer | NCT05924776 | Advanced Ovaria... | Plasmodium immu... | 18 Years - 80 Years | CAS Lamvac Biotech Co., Ltd. | |
| The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer | NCT04065009 | Advanced Ovaria... | Ropivacaine Saline Solution | 18 Years - 80 Years | Karolinska Institutet | |
| Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin | NCT03161132 | Advanced Ovaria... | Olaparib Pegylated Lipos... | 18 Years - | Grupo Español de Investigación en Cáncer de Ovario | |
| SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS | NCT04862325 | Advanced Ovaria... | Multimodal Preh... | 18 Years - | Hospital Clinic of Barcelona | |
| Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer | NCT04360629 | Advanced Ovaria... | Tranexamic Acid normal saline | 20 Years - 70 Years | Fudan University | |
| Advanced Ovarian Cancer and Sexuality Phase 1 | NCT00488202 | Ovarian Cancer Sexual Function | 19 Years - 65 Years | University of British Columbia | ||
| SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS | NCT04862325 | Advanced Ovaria... | Multimodal Preh... | 18 Years - | Hospital Clinic of Barcelona | |
| Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer | NCT03611179 | Advanced Ovaria... | Bevacizumab | 18 Years - | Assiut University | |
| Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | NCT01989546 | Advanced Ovaria... Primary Periton... Advanced Breast... Advanced Solid ... | BMN 673 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing | NCT00381173 | Breast Cancer Ovarian Cancer Prostate Cancer Colon Cancer Renal Cancer | Cyclophosphamid... | 18 Years - | Eisai Inc. | |
| Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. | NCT01844986 | Newly Diagnosed Advanced Ovaria... FIGO Stage III-... BRCA Mutation Complete Respon... Partial Respons... First Line Plat... | Olaparib 300mg ... | 18 Years - 130 Years | AstraZeneca | |
| Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | NCT01989546 | Advanced Ovaria... Primary Periton... Advanced Breast... Advanced Solid ... | BMN 673 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer | NCT05009082 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Carboplatin Paclitaxel Bevacizumab Niraparib | 18 Years - | AGO Study Group | |
| Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors | NCT01290471 | Advanced Solid ... Advanced Ovaria... | U3-1565 | 18 Years - | Daiichi Sankyo | |
| Primary Debulking Surgery Including Bowel Resection in Advanced Stage Ovarian Cancer Using Caiman® Technology | NCT03219242 | Ovarian Cancer | Caiman® device | 18 Years - 75 Years | Catholic University of the Sacred Heart | |
| ULTRA-LAP Trial: Laparoscopic Debulking Surgery (LDS) in Advanced Ovarian Cancer | NCT05862740 | Ovarian Cancer | Laparoscopic De... Standard laparo... | 18 Years - | Azienda Ospedaliera di Padova | |
| Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer | NCT00494442 | Ovarian Neoplas... | KU-0059436 (AZD... KU-0059436 (AZD... | 18 Years - 130 Years | AstraZeneca | |
| ULTRA-LAP Trial: Laparoscopic Debulking Surgery (LDS) in Advanced Ovarian Cancer | NCT05862740 | Ovarian Cancer | Laparoscopic De... Standard laparo... | 18 Years - | Azienda Ospedaliera di Padova | |
| Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP® | NCT03878849 | Advanced Ovaria... | 2X-121 2X-121 DRP® | 18 Years - | Allarity Therapeutics | |
| Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer | NCT00628251 | Ovarian Neoplas... | AZD2281 Liposomal Doxor... AZD2281 | 18 Years - 130 Years | AstraZeneca | |
| Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer | NCT04830709 | Ovarian Cancer | 18 Years - 130 Years | AstraZeneca | ||
| Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer | NCT00628251 | Ovarian Neoplas... | AZD2281 Liposomal Doxor... AZD2281 | 18 Years - 130 Years | AstraZeneca | |
| The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial | NCT03158935 | Advanced Ovaria... Malignant Melan... | Cyclophosphamid... Fludarabine Pembrolizumab Tumor-Infiltrat... Interleukin-2 (... | 18 Years - | University Health Network, Toronto | |
| Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer | NCT01462149 | Advanced Ovaria... | Neoadjuvant che... Carboplatin | 20 Years - 80 Years | Asan Medical Center | |
| Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | NCT01989546 | Advanced Ovaria... Primary Periton... Advanced Breast... Advanced Solid ... | BMN 673 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer | NCT00130520 | Ovarian Neoplas... | bevacizumab erlotinib | 18 Years - | University of Arizona | |
| Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer | NCT04556539 | Advanced Ovaria... | SC10914 | 18 Years - 99 Years | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | |
| Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR) | NCT02054351 | Ovarian Cancer | IMAB027 | 18 Years - | Astellas Pharma Inc | |
| A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP) | NCT00516373 | Ovarian Neoplas... BRCA1 Protein BRCA2 Protein | KU-0059436 (AZD... | 18 Years - 130 Years | AstraZeneca | |
| A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer | NCT05775549 | Advanced Ovaria... | None (Observati... | 18 Years - 130 Years | AstraZeneca | |
| Adjuvant Whole Abdominal Intensity Modulated Radiotherapy (IMRT) for High Risk Stage FIGO III Patients With Ovarian Cancer | NCT00527631 | Ovarian Cancer | whole abdomen i... | 18 Years - 75 Years | Heidelberg University | |
| Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer | NCT05794659 | Advanced Ovaria... | AST-201 Paclitaxel Carboplatin Placebo rhuGM-CSF(Granu... | 18 Years - | Aston Sci. Inc. | |
| A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer | NCT05775549 | Advanced Ovaria... | None (Observati... | 18 Years - 130 Years | AstraZeneca | |
| Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR) | NCT02054351 | Ovarian Cancer | IMAB027 | 18 Years - | Astellas Pharma Inc | |
| A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer | NCT00831636 | Ovarian Cancer | CP-4055 CP-4055 | 18 Years - | Clavis Pharma | |
| Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients | NCT03737643 | Advanced Ovaria... | Bevacizumab Durvalumab Olaparib Placebo olapari... Durvalumab plac... Carboplatin+Pac... | 18 Years - 130 Years | AstraZeneca | |
| The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial | NCT03158935 | Advanced Ovaria... Malignant Melan... | Cyclophosphamid... Fludarabine Pembrolizumab Tumor-Infiltrat... Interleukin-2 (... | 18 Years - | University Health Network, Toronto | |
| Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer | NCT00494442 | Ovarian Neoplas... | KU-0059436 (AZD... KU-0059436 (AZD... | 18 Years - 130 Years | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
